Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 3 |
List of Tables | 4 | 1 |
List of Figures | 4 | 1 |
Introduction | 5 | 1 |
Global Markets Direct Report Coverage | 5 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Overview | 6 | 1 |
Therapeutics Development | 7 | 3 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Products under Development by Stage of Development | 7 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Products under Development by Therapy Area | 8 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Products under Development by Indication | 9 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Pipeline Products Glance | 10 | 2 |
Late Stage Products | 10 | 1 |
Early Stage Products | 11 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Products under Development by Companies | 12 | 2 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Products under Development by Universities/Institutes | 14 | 2 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Therapeutics Assessment | 16 | 4 |
Assessment by Monotherapy/Combination Products | 16 | 1 |
Assessment by Mechanism of Action | 17 | 1 |
Assessment by Route of Administration | 18 | 1 |
Assessment by Molecule Type | 19 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Companies Involved in Therapeutics Development | 20 | 4 |
Angion Biomedica Corp. | 20 | 1 |
Boehringer Ingelheim GmbH | 21 | 1 |
Merck &Co., Inc. | 22 | 1 |
Novartis AG | 23 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Drug Profiles | 24 | 8 |
ANG-3586 Drug Profile | 24 | 1 |
BI-689648 Drug Profile | 25 | 1 |
osilodrostat phosphate Drug Profile | 26 | 2 |
Small Molecule to Inhibit CYP11B2 for Cardiovascular Disease Drug Profile | 28 | 1 |
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases Drug Profile | 29 | 1 |
Small Molecules to Inhibit CYP17 and CYP11B2 for Prostate Cancer Drug Profile | 30 | 1 |
Small Molecules to Inhibit CYP19 and CYP11B2 for Cardiovascular Diseases Drug Profile | 31 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Dormant Projects | 32 | 1 |
Cytochrome P450 11B2 Mitochondrial (Aldosterone Synthase or Cytochrome P450Aldo or Cytochrome P450C18 or Steroid 18 Hydroxylase or CYP11B2 or EC 1.14.15.4 or EC 1.14.15.5) Discontinued Products | 33 | 1 |
Appendix | 34 | 2 |
Methodology | 34 | 1 |
Coverage | 34 | 1 |
Secondary Research | 34 | 1 |
Primary Research | 34 | 1 |
Expert Panel Validation | 34 | 1 |
Contact Us | 34 | 1 |
Disclaimer | 35 | 1 |